Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 24 | 2025 | 871 | 4.220 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2024 | 92 | 4.110 |
Why?
|
| Receptors, Antigen, T-Cell | 16 | 2024 | 498 | 3.690 |
Why?
|
| T-Lymphocytes | 23 | 2025 | 1805 | 3.680 |
Why?
|
| CD5 Antigens | 3 | 2024 | 36 | 1.510 |
Why?
|
| Graft vs Host Disease | 4 | 2025 | 622 | 1.220 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2025 | 443 | 1.010 |
Why?
|
| Antigens, Neoplasm | 6 | 2024 | 407 | 0.970 |
Why?
|
| Cytotoxicity, Immunologic | 6 | 2025 | 277 | 0.970 |
Why?
|
| Cell Engineering | 2 | 2023 | 21 | 0.890 |
Why?
|
| Lymphoma, T-Cell | 1 | 2024 | 65 | 0.840 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 4 | 2025 | 26 | 0.820 |
Why?
|
| Immunologic Memory | 4 | 2025 | 199 | 0.720 |
Why?
|
| Gammaretrovirus | 2 | 2020 | 6 | 0.700 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 295 | 0.660 |
Why?
|
| Lymphocyte Activation | 7 | 2020 | 724 | 0.660 |
Why?
|
| Leukemia | 1 | 2023 | 378 | 0.650 |
Why?
|
| Gene Expression | 4 | 2020 | 1615 | 0.640 |
Why?
|
| Genetic Vectors | 3 | 2020 | 967 | 0.630 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 71 | 0.620 |
Why?
|
| Antigens, CD7 | 2 | 2018 | 11 | 0.600 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2024 | 567 | 0.560 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 795 | 0.550 |
Why?
|
| Listeriosis | 2 | 2014 | 21 | 0.540 |
Why?
|
| Listeria monocytogenes | 2 | 2014 | 32 | 0.540 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 808 | 0.540 |
Why?
|
| Animals | 25 | 2025 | 36308 | 0.520 |
Why?
|
| Graft Rejection | 1 | 2020 | 624 | 0.510 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 1191 | 0.500 |
Why?
|
| Mice | 20 | 2025 | 18845 | 0.500 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2013 | 120 | 0.470 |
Why?
|
| Genomics | 1 | 2023 | 1672 | 0.460 |
Why?
|
| Lymphoma | 1 | 2017 | 335 | 0.420 |
Why?
|
| Antigens, CD19 | 4 | 2024 | 181 | 0.420 |
Why?
|
| Hematologic Neoplasms | 3 | 2022 | 296 | 0.420 |
Why?
|
| Tissue Donors | 1 | 2017 | 522 | 0.410 |
Why?
|
| Cell Line, Tumor | 9 | 2025 | 3730 | 0.410 |
Why?
|
| Signal Transduction | 5 | 2025 | 4889 | 0.410 |
Why?
|
| Cell Proliferation | 4 | 2020 | 2540 | 0.400 |
Why?
|
| Transduction, Genetic | 3 | 2020 | 296 | 0.390 |
Why?
|
| Humans | 35 | 2025 | 133589 | 0.380 |
Why?
|
| Apoptosis | 5 | 2024 | 1933 | 0.370 |
Why?
|
| Immunological Synapses | 2 | 2025 | 27 | 0.370 |
Why?
|
| Neoplasms | 3 | 2022 | 3012 | 0.370 |
Why?
|
| Cell Differentiation | 3 | 2020 | 2026 | 0.360 |
Why?
|
| Interleukin-15 | 3 | 2020 | 96 | 0.350 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2024 | 990 | 0.310 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 170 | 0.310 |
Why?
|
| Transgenes | 3 | 2020 | 345 | 0.310 |
Why?
|
| Chronic Disease | 2 | 2024 | 1252 | 0.310 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 2159 | 0.280 |
Why?
|
| Killer Cells, Natural | 3 | 2020 | 354 | 0.270 |
Why?
|
| Transcription Factors | 2 | 2014 | 2704 | 0.250 |
Why?
|
| CD28 Antigens | 3 | 2025 | 81 | 0.250 |
Why?
|
| Cell Line | 2 | 2020 | 2843 | 0.230 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 63 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 357 | 0.230 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 117 | 0.220 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 81 | 0.210 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 177 | 0.210 |
Why?
|
| Bone Marrow Diseases | 1 | 2022 | 42 | 0.200 |
Why?
|
| Dasatinib | 1 | 2022 | 50 | 0.200 |
Why?
|
| Cellular Senescence | 1 | 2024 | 201 | 0.190 |
Why?
|
| Immunophenotyping | 2 | 2020 | 342 | 0.190 |
Why?
|
| Macaca mulatta | 1 | 2023 | 513 | 0.180 |
Why?
|
| Blood Platelets | 1 | 2024 | 341 | 0.180 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 676 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2021 | 244 | 0.160 |
Why?
|
| Immunotherapy | 3 | 2024 | 744 | 0.160 |
Why?
|
| Glypicans | 1 | 2020 | 41 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2022 | 821 | 0.160 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 156 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1313 | 0.160 |
Why?
|
| Recurrence | 1 | 2023 | 1470 | 0.150 |
Why?
|
| Interleukins | 1 | 2020 | 132 | 0.150 |
Why?
|
| Genetic Engineering | 1 | 2020 | 164 | 0.150 |
Why?
|
| Mice, Inbred NOD | 4 | 2020 | 316 | 0.150 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 4748 | 0.150 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 292 | 0.150 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2017 | 8 | 0.140 |
Why?
|
| 4-1BB Ligand | 1 | 2017 | 11 | 0.140 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2017 | 16 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 228 | 0.140 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2017 | 32 | 0.140 |
Why?
|
| Gene Editing | 1 | 2020 | 205 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 713 | 0.140 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2017 | 69 | 0.140 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 286 | 0.140 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 77 | 0.140 |
Why?
|
| CD3 Complex | 1 | 2017 | 93 | 0.130 |
Why?
|
| Mice, Knockout | 3 | 2014 | 3961 | 0.130 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 273 | 0.130 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2016 | 20 | 0.130 |
Why?
|
| Gene Silencing | 1 | 2017 | 251 | 0.130 |
Why?
|
| Tumor Escape | 1 | 2016 | 65 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 215 | 0.120 |
Why?
|
| Transplantation Chimera | 1 | 2015 | 42 | 0.120 |
Why?
|
| Cell Survival | 2 | 2017 | 892 | 0.120 |
Why?
|
| Flow Cytometry | 2 | 2017 | 836 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 233 | 0.120 |
Why?
|
| Adoptive Transfer | 2 | 2013 | 241 | 0.110 |
Why?
|
| Gene Expression Regulation | 3 | 2014 | 2661 | 0.110 |
Why?
|
| Seizures | 1 | 2020 | 892 | 0.110 |
Why?
|
| Mice, SCID | 3 | 2022 | 612 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2020 | 3170 | 0.110 |
Why?
|
| Ovalbumin | 1 | 2014 | 321 | 0.110 |
Why?
|
| Receptor, Notch1 | 1 | 2014 | 79 | 0.110 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 317 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 560 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2016 | 373 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 996 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 2527 | 0.080 |
Why?
|
| Biomarkers | 1 | 2020 | 3411 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 1407 | 0.080 |
Why?
|
| Homeostasis | 1 | 2013 | 751 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 495 | 0.070 |
Why?
|
| Myeloid Cells | 2 | 2018 | 119 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1400 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 4789 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 398 | 0.060 |
Why?
|
| Female | 5 | 2025 | 71528 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2010 | 1061 | 0.060 |
Why?
|
| Cytokines | 2 | 2022 | 1397 | 0.050 |
Why?
|
| Male | 3 | 2017 | 65783 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2021 | 11 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 158 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2022 | 335 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 384 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 453 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2020 | 179 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2021 | 692 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 563 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 1101 | 0.040 |
Why?
|
| fas Receptor | 1 | 2017 | 50 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 57 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 805 | 0.030 |
Why?
|
| Lentivirus | 1 | 2017 | 86 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2017 | 93 | 0.030 |
Why?
|
| Interleukin-7 | 1 | 2017 | 50 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 506 | 0.030 |
Why?
|
| Cell Death | 1 | 2017 | 249 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2017 | 250 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 494 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2016 | 101 | 0.030 |
Why?
|
| Child | 3 | 2022 | 25711 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2016 | 141 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 262 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1314 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 487 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5491 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1831 | 0.020 |
Why?
|
| Pediatrics | 1 | 2021 | 1209 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 20512 | 0.020 |
Why?
|
| Blood Cells | 1 | 2010 | 55 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 6276 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2010 | 83 | 0.020 |
Why?
|
| Spleen | 1 | 2010 | 291 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 633 | 0.020 |
Why?
|
| Adult | 2 | 2022 | 31933 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2010 | 374 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 278 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 590 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 627 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1849 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2785 | 0.020 |
Why?
|
| United States | 1 | 2021 | 11654 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 7203 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 3970 | 0.010 |
Why?
|
| Cell Movement | 1 | 2009 | 919 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2898 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17437 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 13003 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 9897 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 21699 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 29349 | 0.010 |
Why?
|